Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Premature Menopause

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39 result(s) found for: Premature Menopause. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-004511-30 Sponsor Protocol Number: POF01 Start Date*: 2013-01-16
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: A randomised controlled trial to compare the effect of micronized progesterone and Medroxyprogesterone Acetate on the vascular elasticity, lipid profile and coagulation cascade of women with premat...
    Medical condition: Premature ovarian failure.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10036602 Premature ovarian failure LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006706-69 Sponsor Protocol Number: DUAG9V1.03_10.06.2022 Start Date*: 2022-06-22
    Sponsor Name:Psychiatry – Aalborg University Hospital, Unit for Psychiatric Research
    Full Title: Lithium versus cariprazine in the acute phase treatment of bipolar depression: a pragmatic head-to-head open, randomized multicenter study. The 9th study of the Danish University Antidepressant Gro...
    Medical condition: Bipolar disorder, current depressive episode.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10004911 Bipolar affective disorder, depressed LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005328-17 Sponsor Protocol Number: MO28048 Start Date*: 2012-04-26
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase III prospective, two-cohort non-randomised, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in pati...
    Medical condition: HER2-positive primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed) DE (Completed) ES (Completed) FR (Completed) HU (Completed) PT (Completed) GB (Completed) NO (Completed) IT (Completed) GR (Completed) LT (Completed) PL (Completed) SI (Completed) SK (Completed) FI (Completed) BG (Completed) NL (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004682-39 Sponsor Protocol Number: KFJ-2020-02_NORMOSANG Start Date*: 2020-11-16
    Sponsor Name:Thomayerova nemocnice
    Full Title: Pilot, open-label, monocentric study evaluating safety and clinical effect of application of NORMOSANG® in patients with COVID-19 disease
    Medical condition: Patients with COVID -19 disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001830-32 Sponsor Protocol Number: RC31/17/0448 Start Date*: 2019-12-18
    Sponsor Name:University Hospital Toulouse
    Full Title: Phase III Trial to assess impact of ultra-long versus long down-regulation protocol on IVF/ICSI outcomes in infertile women presenting with adenomyosis.
    Medical condition: Infertilty in women with adenomyosis.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004199-18 Sponsor Protocol Number: E2007-A001-206 Start Date*: 2006-03-22
    Sponsor Name:Eisai Limited
    Full Title: A Double-blind, Placebo-controlled, Dose-escalation, Parallel Group Study of E2007 given as Adjunctive Therapy in Patients with Refractory Partial Seizures
    Medical condition: E2007 is given as adjunctive therapy in patients with refractory partial seizures
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) DE (Completed) GB (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-005936-31 Sponsor Protocol Number: SMX18-001 Start Date*: 2021-05-24
    Sponsor Name:Sermonix Pharmaceuticals
    Full Title: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic E...
    Medical condition: Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002439-33 Sponsor Protocol Number: MeIn/08/ZOF+HCTZ-HYP/001 Start Date*: 2008-06-26
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
    Full Title: EFFICACY AND SAFETY OF ZOFENOPRIL + HYDROCHLOROTHIAZIDE COMBINATION VS IRBESARTAN + HYDROCHLOROTHIAZIDE COMBINATION IN ESSENTIAL HYPERTENSIVE PATIENTS NOT CONTROLLED BY PREVIOUS MONOTHERAPY
    Medical condition: Patients with essential hypertension and with at least one additional cardiovascular risk factor, not controlled by a previous monotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) LT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004033-15 Sponsor Protocol Number: B2C108562 Start Date*: 2006-09-29
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 and 400...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004422-31 Sponsor Protocol Number: FKS518-002 Start Date*: 2021-02-23
    Sponsor Name:Fresenius Kabi SwissBioSim GmbH
    Full Title: A Double-blind, Randomized, Multicenter, Multiple-dose, 2-arm, Parallel-group Study to Evaluate Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 - Proposed Biosimilar to Denosumab w...
    Medical condition: Osteoporosis in Postmenopausal Women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10005992 Bone metabolism disorders HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-003401-87 Sponsor Protocol Number: SND103285 Start Date*: 2006-02-15
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BE (Completed) FR (Completed) EE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000995-33 Sponsor Protocol Number: EuroNet-PHL-C1 Start Date*: 2006-12-13
    Sponsor Name:Martin-Luther-University Halle-Wittenberg
    Full Title: EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents
    Medical condition: 1st and 2nd line therapy for childhood Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) GB (Completed) SE (Completed) AT (Completed) FR (Completed) IE (Completed) ES (Completed) DK (Completed) PL (Completed) BE (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2005-003400-11 Sponsor Protocol Number: SND103288 Start Date*: 2005-11-09
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An Eight-week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Group, Fixed-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.0 mg/day) or ...
    Medical condition: Major Depressive Disorder (MDD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) EE (Prematurely Ended) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001724-19 Sponsor Protocol Number: CLI-06467AA1-01 Start Date*: 2018-10-04
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A randomised, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CHF6467 after single and repeated ascending doses in su...
    Medical condition: Diabetic Neuropathic Foot Ulcers (DFU) Texas Scale Grade 1A and 2A
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-002781-31 Sponsor Protocol Number: PQBirch301 Start Date*: 2017-02-16
    Sponsor Name:Allergy Therapeutics (UK) Ltd
    Full Title: A multi-centre, double-blind, randomised, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Birch Modified Allergen Tyrosine adsorbed + MPL in the prevention of season...
    Medical condition: Seasonal allergic rhinoconjunctivitis due to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014962 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012189-30 Sponsor Protocol Number: BC1-09 Start Date*: 2009-10-30
    Sponsor Name:Algeta ASA
    Full Title: An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy
    Medical condition: Breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for further endocrine therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004241-36 Sponsor Protocol Number: ML42502 Start Date*: 2021-03-23
    Sponsor Name:Roche Farma S.A
    Full Title: TIME AND MOTION STUDY OF A SUBCUTANEOUS FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER.
    Medical condition: EARLY BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005975-17 Sponsor Protocol Number: MO28113 Start Date*: 2012-08-17
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A two-part, randomized Phase II, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in ...
    Medical condition: Women with recurrent platinum-resistant or refractory epithelial ovarian cancer and low HER3 mRNA expression.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed) NL (Completed) SE (Completed) BE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003138-16 Sponsor Protocol Number: Ed001 Start Date*: 2005-08-26
    Sponsor Name:R+ D department, Hull and East Yorkshire NHS Hospital Trust
    Full Title: A clinical observational study to assess the effectiveness of Strontium Ranelate on bone protection in osteoporotic patients pre-treated with bisphosphonates.
    Medical condition: Postmenopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002848-41 Sponsor Protocol Number: CAPL180A2207 Start Date*: 2008-08-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemia
    Medical condition: familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054380 Familial hypercholesterolemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 09:47:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA